Eisai
4523.T
£20.74
Share price
0.95%
Change (1 day)
-34.27%
Change (1 year)
Categories
Eisai is a Japanese pharmaceutical company that is engaged in the R&D of drugs for the treatment of dementia and Alzheimer.
Revenue for Eisai (4523.T)
Revenue in 2024 (TTM): £4.03 Billion
According to Eisai's latest financial reports the company's current revenue (TTM 
) is £3.92 Billion. In 2023 the company made a revenue of £4.15 Billion a decrease over the revenue in the year 2022 that were of £4.59 Billion. The revenue is the total amount of income that a company generates by the sale of goods or services. Unlike with the earnings no expenses are subtracted.
Revenue history for Eisai from 2009 to 2024
Annual revenue
| Year | Revenue | Change |
|---|---|---|
| 2024 (TTM) | £4.03 B | -2.88% |
| 2023 | £4.15 B | -9.56% |
| 2022 | £4.59 B | -2.59% |
| 2021 | £4.71 B | -3.69% |
| 2020 | £4.89 B | 5.81% |
| 2019 | £4.62 B | 3.11% |
| 2018 | £4.48 B | 19.45% |
| 2017 | £3.75 B | -5.84% |
| 2016 | £3.98 B | 25.95% |
| 2015 | £3.16 B | -5.26% |
| 2014 | £3.34 B | -7.14% |
| 2013 | £3.59 B | -17.48% |
| 2012 | £4.36 B | -18.59% |
| 2011 | £5.35 B | -11.95% |
| 2010 | £6.08 B | 17.85% |
| 2009 | £5.16 B |